AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35491481 — intervention group
Group type: EXPERIMENTAL
Intervention: TASC D
Number of subjects: 1364
Study 35491481 — intervention group
Group type: EXPERIMENTAL
Intervention: Technical success rate
Number of subjects: 1364
Study 35491481 — intervention group
Group type: EXPERIMENTAL
Intervention: Complications
Number of subjects: 1364
Study 35491481 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors for TLR
Number of subjects: 1364
Study 35491482 — intervention group
Group type: EXPERIMENTAL
Intervention: β-blockers
Number of subjects: 3075
Study 35491482 — intervention group
Group type: COMPARATOR
Intervention: No β-blockers
Number of subjects: 3075
Study 35491511 — intervention group
Group type: EXPERIMENTAL
Intervention: STAR-OX40 T-cell therapy
Number of subjects: 18
Study 35491519 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose glibenclamide
Number of subjects: 0
Study 35491519 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35491674 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary sugar intake
Number of subjects: 68
Study 35491674 — intervention group
Group type: COMPARATOR
Intervention: Low dietary sugar intake
Number of subjects: 68
Study 35491674 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucrose ingestion
Number of subjects: 68
Study 35491674 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy weight
Number of subjects: 68
Study 35491674 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight
Number of subjects: 68
Study 35491674 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 68
Study 35491674 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 68
Study 35491738 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold atmospheric plasma
Number of subjects: 0
Study 35491738 — intervention group
Group type: COMPARATOR
Intervention: Topical ivermectin
Number of subjects: 0
Study 35491783 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative dementia care management
Number of subjects: 183
Study 35491783 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperation with other healthcare providers
Number of subjects: 183
Study 35491783 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing care
Number of subjects: 183
Study 35491783 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 183
Study 35491783 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher number of tasks
Number of subjects: 183
Study 35492244 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma neurofilament light (NfL) levels in FTD syndromes and presymptomatic mutation carriers
Number of subjects: 0
Study 35492329 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Fat-Free Muscle Index (L-FFMI)
Number of subjects: 156
Study 35492329 — intervention group
Group type: EXPERIMENTAL
Intervention: Large Total Cross-Sectional Spontaneous Portosystemic Shunt Area (L-TSA)
Number of subjects: 156
Study 35492329 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous presence of L-FFMI and L-TSA
Number of subjects: 156
Study 35492329 — intervention group
Group type: EXPERIMENTAL
Intervention: L-FFMI
Number of subjects: 156
Study 35492329 — intervention group
Group type: EXPERIMENTAL
Intervention: L-TSA
Number of subjects: 156
Study 35492333 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheopheresis (RheoP)
Number of subjects: 0
Study 35492333 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35492338 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Exchange (PE)
Number of subjects: 22
Study 35492338 — intervention group
Group type: COMPARATOR
Intervention: Insulin infusion
Number of subjects: 22
Study 35492586 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0
Study 35492586 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35492873 — intervention group
Group type: EXPERIMENTAL
Intervention: AXL targeting intervention, details on dosage and duration not available
Number of subjects: 0
Study 35492873 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 35492875 — intervention group
Group type: EXPERIMENTAL
Intervention: CCL18 treatment
Number of subjects: 0
Study 35492875 — intervention group
Group type: EXPERIMENTAL
Intervention: Blockade of CCR8
Number of subjects: 0
Study 35493124 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamlanivimab (700 mg) and Etesevimab (1400 mg)
Number of subjects: 769
Study 35493124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 769
Study 35493124 — intervention group
Group type: EXPERIMENTAL
Intervention: Bamlanivimab and Etesevimab
Number of subjects: 769
Study 35493516 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06671008 (1.5-400 ng/kg) as a weekly intravenous (IV) infusion on a 21-day/3-week cycle
Number of subjects: 0
Study 35493739 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial samples from the oral cavity, sputum, and ileum of patients with CD
Number of subjects: 0
Study 35493739 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cavity and sputum microbiota
Number of subjects: 0
Study 35493739 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiota composition in oral cavity and sputum
Number of subjects: 0
Study 35493739 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbiota architecture in oral cavity, sputum, and ileum
Number of subjects: 0
Study 35493739 — intervention group
Group type: EXPERIMENTAL
Intervention: Study of microbiota dysbiosis
Number of subjects: 0
Study 35493925 — intervention group
Group type: EXPERIMENTAL
Intervention: Random Forests (RF) model
Number of subjects: 18209
Study 35493932 — intervention group
Group type: EXPERIMENTAL
Intervention: BAILAMOS™ Latin dance program
Number of subjects: 333
Study 35493932 — intervention group
Group type: COMPARATOR
Intervention: Health education control group
Number of subjects: 333
Study 35494168 — intervention group
Group type: EXPERIMENTAL
Intervention: Pectoralis muscle strength in patients with IPF
Number of subjects: 17
Study 35494168 — intervention group
Group type: COMPARATOR
Intervention: Pectoralis muscle strength in healthy controls
Number of subjects: 17
Study 35495025 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimated glomerular filtration rate (eGFR)
Number of subjects: 2277
Study 35495025 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI)
Number of subjects: 2277
Study 35496758 — intervention group
Group type: EXPERIMENTAL
Intervention: rHIgM22 (0.5 or 2.0 mg/kg)
Number of subjects: 27
Study 35496758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 35497488 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcervical fibroid ablation (TFA) with the Sonata System
Number of subjects: 147
Study 35497778 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazakizumab 25 mg subcutaneously (s.c.) monthly for 12 months
Number of subjects: 10
Study 35497778 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazakizumab for >2.5 years in long-term extension (LTE)
Number of subjects: 10
Study 35497778 — intervention group
Group type: EXPERIMENTAL
Intervention: Clazakizumab treatment
Number of subjects: 10
Study 35497805 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 0
Study 35497805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35497806 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxadustat
Number of subjects: 302
Study 35497806 — intervention group
Group type: COMPARATOR
Intervention: Darbepoetin alfa (DA)
Number of subjects: 302
Study 35497990 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic assessment and management pathway (intervention group)
Number of subjects: 498
Study 35497990 — intervention group
Group type: COMPARATOR
Intervention: Standard management (control group)
Number of subjects: 498
Study 35498010 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-coated balloon (DCB) treatment
Number of subjects: 84
Study 35498017 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in cardiac symptoms from 3 to 12 months after ACS hospitalization
Number of subjects: 0
Study 35498050 — intervention group
Group type: EXPERIMENTAL
Intervention: L-Arginine
Number of subjects: 72
Study 35498050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 35498381 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus low-dose apatinib
Number of subjects: 25
Study 35498781 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous cerebral tissue oxygen saturation (cStO2) monitoring
Number of subjects: 162
Study 35499065 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness Management and Recovery (IMR)
Number of subjects: 0
Study 35499065 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 35499083 — intervention group
Group type: EXPERIMENTAL
Intervention: Hymecromone 1200 mg/d
Number of subjects: 26
Study 35499083 — intervention group
Group type: EXPERIMENTAL
Intervention: Hymecromone 2400 mg/d
Number of subjects: 26
Study 35499083 — intervention group
Group type: EXPERIMENTAL
Intervention: Hymecromone 3600 mg/d
Number of subjects: 26
Study 35499083 — intervention group
Group type: EXPERIMENTAL
Intervention: Hymecromone (all doses combined)
Number of subjects: 26
Study 35499104 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine 10 mg/day, increased to 20 mg/day after 1 week
Number of subjects: 100
Study 35499468 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-interleukin-1β (IL-1β), anti-IL-6, and anti-tumor necrosis factor α
Number of subjects: 10
Study 35499468 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2
Number of subjects: 10
Study 35499468 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral unmethylated INS DNA
Number of subjects: 10
Study 35499468 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmortem pancreatic tissues
Number of subjects: 10
Study 35499706 — intervention group
Group type: EXPERIMENTAL
Intervention: DLG2 overexpression in colon cancer cells
Number of subjects: 0
Study 35499706 — intervention group
Group type: EXPERIMENTAL
Intervention: DLG2 silencing in THP1 cells
Number of subjects: 0
Study 35499706 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6 treatment on bystander COLO205 cells
Number of subjects: 0
Study 35499706 — intervention group
Group type: EXPERIMENTAL
Intervention: Restoration of DLG2 to the colon
Number of subjects: 0
Study 35499827 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonoperative management with antibiotics
Number of subjects: 370
Study 35500016 — intervention group
Group type: EXPERIMENTAL
Intervention: Bexmarilimab (humanized IgG4 antibody against Clever-1)
Number of subjects: 0
Study 35500125 — intervention group
Group type: EXPERIMENTAL
Intervention: NS7CAR T cells
Number of subjects: 20
Study 35500223 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin for 6 months
Number of subjects: 15
Study 35500223 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 15
Study 35500404 — intervention group
Group type: EXPERIMENTAL
Intervention: E7389-LF 2.0 mg/m
Number of subjects: 28
Study 35500404 — intervention group
Group type: EXPERIMENTAL
Intervention: E7389-LF 2.0 mg/m with prophylactic pegfilgrastim
Number of subjects: 28
Study 35500434 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 197
Study 35500613 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient elastography in women with preeclampsia (antepartum)
Number of subjects: 73
Study 35500613 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient elastography in women with preeclampsia (postpartum)
Number of subjects: 73
Study 35500613 — intervention group
Group type: COMPARATOR
Intervention: Transient elastography in healthy controls (antepartum)
Number of subjects: 73
Study 35500613 — intervention group
Group type: COMPARATOR
Intervention: Transient elastography in healthy controls (postpartum)
Number of subjects: 73
Study 35500613 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient elastography in women with preeclampsia (postpartum) with severe features
Number of subjects: 73
Study 35501092 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle behaviours and dietary pattern assessment at baseline, including demographic characteristics, medical history, sleep duration and quality, bowel movements, and regular diet.
Number of subjects: 1500
Study 35501092 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessments including biochemical measurements, blood pressure, carotid ultrasound, echocardiography, electrocardiography, and cardiac magnetic resonance.
Number of subjects: 1500
Study 35501092 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle strength assessment using handgrip dynamometer and MicroFet2 hand-held dynamometer.
Number of subjects: 1500
Study 35501097 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonoclot (glass beaded) test at admission
Number of subjects: 74
Study 35501097 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired Sonoclot assays at day 1 and 3
Number of subjects: 74
Study 35501097 — intervention group
Group type: EXPERIMENTAL
Intervention: HLE (day 1)
Number of subjects: 74
Study 35501097 — intervention group
Group type: COMPARATOR
Intervention: Invasive ventilation group
Number of subjects: 74
Study 35501097 — intervention group
Group type: EXPERIMENTAL
Intervention: HLE
Number of subjects: 74
Study 35501097 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of HLE
Number of subjects: 74
Study 35501097 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased C reactive protein
Number of subjects: 74
Study 35501097 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased platelet function
Number of subjects: 74
Study 35501102 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma (P)-myoglobin and P-creatine phosphokinase analyzed at 6-hourly intervals after admission for 48 hours and after surgical fixation or fasciotomy for 24 hours.
Number of subjects: 0
Study 35501102 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers of muscle cell damage (P-myoglobin and P-creatine phosphokinase)
Number of subjects: 0
Study 35501102 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analyses of biomarkers
Number of subjects: 0
Study 35501309 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (0.5 mg/kg)
Number of subjects: 9
Study 35501309 — intervention group
Group type: EXPERIMENTAL
Intervention: (2R,6R)-HNK (10 mg/kg)
Number of subjects: 9
Study 35501309 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 9
Study 35501330 — intervention group
Group type: EXPERIMENTAL
Intervention: Placental DNA methylation and gene expression targets for birthweight GWAS loci
Number of subjects: 0
Study 35501330 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylation influence on gene expression
Number of subjects: 0
Study 35501330 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-trait colocalization
Number of subjects: 0
Study 35501359 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning-based prediction model (Catboost)
Number of subjects: 1568
Study 35501592 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg single oral dose
Number of subjects: 175
Study 35501592 — intervention group
Group type: EXPERIMENTAL
Intervention: NUP153 and SVEP1 gene variation
Number of subjects: 175
Study 35501763 — intervention group
Group type: EXPERIMENTAL
Intervention: Informal caregiver-related factors and psychological burden assessments (WHOQOL-BREF, NCCN-Distress Thermometer, GAD-7, PHQ-9)
Number of subjects: 240
Study 35501763 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical records and nurse-reported data
Number of subjects: 240
Study 35501763 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable regression models
Number of subjects: 240
Study 35502192 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular outcomes at 12-month follow-up (including incident AF, stroke, TIA, and myocardial infarction)
Number of subjects: 1222
Study 35502192 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in function, depression, anxiety, fatigue, and quality of life
Number of subjects: 1222
Study 35502515 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-delivered safety planning
Number of subjects: 31
Study 35502515 — intervention group
Group type: COMPARATOR
Intervention: Provider-delivered safety planning
Number of subjects: 31
Study 35502609 — intervention group
Group type: EXPERIMENTAL
Intervention: Polatuzumab vedotin with bendamustine and rituximab (Pola-BR)
Number of subjects: 21
Study 35502771 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional Flow Reserve (FFR)
Number of subjects: 1564
Study 35502771 — intervention group
Group type: EXPERIMENTAL
Intervention: Instantaneous Wave-Free Ratio (iFR)
Number of subjects: 1564
Study 35502871 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric emptying scintigraphy (GES) meal
Number of subjects: 109
Study 35502871 — intervention group
Group type: EXPERIMENTAL
Intervention: Water load satiety test (WLST)
Number of subjects: 109
Study 35502871 — intervention group
Group type: COMPARATOR
Intervention: Delayed gastric emptying
Number of subjects: 109
Study 35503163 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg qw
Number of subjects: 2677
Study 35503163 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg q2w
Number of subjects: 2677
Study 35503163 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg qw or q2w
Number of subjects: 2677
Study 35503163 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 2677
Study 35503244 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunnyside (6-week cognitive behavioral therapy-based web-based intervention)
Number of subjects: 22
Study 35503244 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunnyside Plus (6-week cognitive behavioral therapy-based web-based intervention with additional education and support for human milk feeding)
Number of subjects: 22
Study 35503708 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 47
Study 35503774 — intervention group
Group type: EXPERIMENTAL
Intervention: Below-the-ankle (BTA) intervention
Number of subjects: 0
Study 35504121 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantar pressure in the lateral forefoot
Number of subjects: 25
Study 35504121 — intervention group
Group type: EXPERIMENTAL
Intervention: Early stance center of pressure
Number of subjects: 25
Study 35504168 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase angle measurement on ICU admission
Number of subjects: 1023
Study 35504168 — intervention group
Group type: EXPERIMENTAL
Intervention: APACHE III score
Number of subjects: 1023
Study 35504168 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of malignancy
Number of subjects: 1023
Study 35504244 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg intravenously every two weeks for 26 cycles
Number of subjects: 27
Study 35504641 — intervention group
Group type: EXPERIMENTAL
Intervention: cPRO assessments (pain, fatigue, physical function, depression, anxiety and supportive care needs) before medical oncology visits.
Number of subjects: 4000
Study 35504641 — intervention group
Group type: EXPERIMENTAL
Intervention: cPRO implementation over 12 months.
Number of subjects: 4000
Study 35504641 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-reported healthcare utilisation and quality, symptoms and health-related quality of life measures at baseline, 6 and 12 months.
Number of subjects: 4000
Study 35504641 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus groups or interviews with patients (n=50) and surveys with clinicians and administrators (n=40).
Number of subjects: 4000
Study 35504640 — intervention group
Group type: EXPERIMENTAL
Intervention: Decentralised, one-stop-shop model of care
Number of subjects: 0
Study 35505001 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with SB
Number of subjects: 36
Study 35505238 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal reaction (IDR) test in likely insulin allergy patients
Number of subjects: 52
Study 35505238 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal reaction (IDR) test in possible insulin allergy patients
Number of subjects: 52
Study 35505238 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal reaction (IDR) test in unlikely insulin allergy patients
Number of subjects: 52
Study 35505238 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal reaction (IDR) test in case-control study
Number of subjects: 52
Study 35505238 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin prick and serum anti-insulin IgE tests in case-control study
Number of subjects: 52
Study 35505290 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored dietary counseling for six months, focusing on increasing protein and energy intake.
Number of subjects: 199
Study 35505290 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually tailored dietary counseling for six months.
Number of subjects: 199
Study 35505290 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 199
Study 35505330 — intervention group
Group type: EXPERIMENTAL
Intervention: FFI-RSN (Foot Function Index revised short form)
Number of subjects: 139
Study 35505330 — intervention group
Group type: EXPERIMENTAL
Intervention: FFI-RSN
Number of subjects: 139
Study 35505358 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary educational intervention for hospital staff
Number of subjects: 23
Study 35505383 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted motivational interviewing social network intervention (MI-SNI)
Number of subjects: 15
Study 35505384 — intervention group
Group type: COMPARATOR
Intervention: High-risk group (based on the predictive model)
Number of subjects: 470
Study 35505404 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral-based transition to continued rehabilitation in the home
Number of subjects: 190
Study 35505418 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy men)
Number of subjects: 34
Study 35505418 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group (patients with PE)
Number of subjects: 34
Study 35505418 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group (patients with PE) after Nuss surgery
Number of subjects: 34
Study 35506108 — intervention group
Group type: EXPERIMENTAL
Intervention: GSK2586881 (0.1, 0.2, 0.4, or 0.8 mg/kg, single intravenous dose)
Number of subjects: 0